

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/092,088
Filing Date	March 6, 2002
First Named Inventor	J. Kevin JUDICE
Art Unit	1653
Examiner Name	David LUKTON
Attorney Docket Number	P-022-RC1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X	A1	US-4,497,802	02-05-1985	Debono	
X	A2	US-4,630,433	01-27-1987	Hunt et al.	
X	A3	US-4,643,987	02-17-1987	Nagarajan et al.	
X	A4	US-4,661,470	04-28-1987	Malabarba et al.	
X	A5	US-4,698,327	10-06-1987	Nagarajan et al.	
X	A6	US-4,914,187	04-03-1990	Malabarba et al.	
X	A7	US-5,534,420	07-09-1996	Debono et al.	
X	A8	US-5,591,714	01-07-1997	Nagarajan et al.	
X	A9	US-5,750,509	05-12-1998	Malabarba et al.	
X	A10	US-5,840,684	11-24-1998	Cooper et al.	
X	A11	US-5,843,889	12-01-1998	Cooper et al.	
X	A12	US-5,916,873	06-29-1999	Cooper et al.	
X	A13	US-5,919,756	07-06-1999	Cooper et al.	
X	A14	US-5,952,310	09-14-1999	Thompson et al.	
X	A15	US-5,952,466	09-14-1999	Berglund et al.	
X	A16	US-5,977,062	11-02-1999	Cooper et al.	
X	A17	US-5,977,063	11-02-1999	Thompson et al.	
X	A18	US-5,998,581	12-07-1999	Berglund et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
DL	B1	WO 88/06600 A1	09-07-1988	Gruppo Lepetit S.P.A.		
DL	B2	WO 90/11300 A1	10-04-1990	Gruppo Lepetit S.P.A.		
DL	B3	WO 97/28812 A2	08-14-1997	Giuliani S. A.		
DL	B4	WO 97/34623 A1	09-25-1997	Transcell Technologies, Inc.		
DL	B5	WO 97/38702 A1	10-23-1997	Eli Lilly and Company		
DL	B6	WO 97/40067 A1	10-30-1997	Biosearch Italia S.P.A.		
DL	B7	WO 98/21952 A1	05-28-1998	Eli Lilly and Company		
DL	B8	WO 98/52589 A1	11-26-1998	Eli Lilly and Company		
DL	B9	WO 98/52592 A1	11-26-1998	Eli Lilly and Company		
DL	B10	WO 99/42476 A1	08-26-1999	Advanced Medicine, Inc.		
DL	B11	WO 99/56760 A1	11-11-1999	Eli Lilly and Company		
DL	B12	WO 00/04044 A1	01-27-2000	Princeton University		
DL	B13	EP 0 182 157 A2	05-28-1986	Gruppo Lepetit S.P.A.		

Examiner Signature	David Lukton	Date Considered	10-18-04
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 15 2003

PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for FORM 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

Complete If Known

Application Number	10/092,088
Filing Date	March 6, 2002
First Named Inventor	J. Kevin JUDICE
Art Unit	1653
Examiner Name	David LUKTON
Attorney Docket Number	P-022-RC1

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
JK	B14	EP 0 351 597 A2	01-24-1990	Gruppo Lepetit S.p.A.		
	B15	EP 0 376 041 A2	07-04-1990	Gruppo Lepetit S.p.A.		
	B16	EP 0 460 448 B1	12-11-1991	Gruppo Lepetit S.p.A.		
	B17	EP 0 525 499 A1	02-03-1993	Gruppo Lepetit S.p.A.		
	B19	EP 0 596 929 B1	07-26-1995	Gruppo Lepetit S.p.A.		
	B19	EP 0 667 353 A1	08-16-1995	Eli Lilly and Company		
	B20	EP 0 801 075 A1	10-15-1997	Eli Lilly and Company		
JK	B21	EP 0 802 199 A2	10-22-1997	Eli Lilly and Company		
	B22	EP 0 816 378 A1	01-07-1998	Eli Lilly and Company		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JK	C1	ALLEN et al., "The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics", The Journal of Antibiotics, Vol. 50, No. 8, pp 677-684 (1997)	
	C2	AXELSEN et al., "A Rational Strategy for Enhancing the Affinity of Vancomycin towards Depsipeptide Ligands", Bioorganic & Medicinal Chemistry 6, pp 877-881 (1998)	
	C3	BOOTH et al., "The Edman Degradation of Vancomycin: Preparation of Vancomycin Hexapeptide", J. Chem. Soc., Chem. Commun., pp 1694-1695 (1987)	
	C4	COOPER et al., "Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity", The Journal of Antibiotics, Vol. 49, No. 6, pp 575-581 (1996)	
	C5	COOPER et al., "Chapter 14. Semisynthetic Glycopeptide Antibiotics", Annual Reports in Medicinal Chemistry, Volume 31, pp 131-140 (1996)	
	C6	FUKUZAWA et al., "Modification of sugar part of glycopeptide antibiotic, vancomycin", Tennen Yuki Kagobutsu Toronkai Koen Yoshishua, 40th, pp 151-156 (1998) (in Japanese with English language translation)	
	C7	GE et al., "Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala", Science, Vol. 284, pp 507-511 (1999)	
JK	C8	KERNS et al., "Synthesis and Antibacterial Activity of Novel Carbohydrate Modified Derivatives of the Glycopeptide Antibiotic Vancomycin", Abstracts of Papers of the 216th ACS National Meeting, Boston, MA, August 23-27, 1998	
	C9	MACKAY et al., "Glycopeptide Antibiotic Activity and the Possible Role of Dimerization: A Model for Biological Signaling", J. Am. Chem. Soc., Vol. 116, pp 4581-4590 (1994)	

Examiner Signature

David Lukton

Date Considered

10-18-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form N-49B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/092,088
Filing Date	March 6, 2002
First Named Inventor	J. Kevin JUDICE
Art Unit	1653
Examiner Name	David LUKTON

Attorney Docket Number P-022-RC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DL</i>	C10	MALABARBA et al., "Amides of De-Acetylglucosaminyl-Deoxy Teicoplanin Active Against Highly Glycopeptide-Resistant Enterococci", Vol. 47, No. 12, pp 1493-1506 (1994)	
	C11	MALABARBA et al., "Glycopeptide resistance in multiple antibiotic-resistant Gram-positive bacteria: a current challenge for novel semi-synthetic glycopeptide derivatives", Eur. J. Med. Chem., Vol. 32, pp 459-478 (1997)	
	C12	MALABARBA et al., "New Semisynthetic Glycopeptides MDL 63,246 and MDL 63,042, and Other Amide Derivatives of Antibiotic A-40,926 against Highly Glycopeptide-resistant VanA Enterococci", The Journal of Antibiotics, Vol. 48, No. 8, pp 869-883 (1995)	
	C13	MALABARBA et al., "Reductive Hydrolysis of the 59,60-Amide Bond of Teicoplanin Antibiotics: A Key Step from Natural to Synthetic Glycopeptides", J. Med. Chem., Vol. 37, pp 2988-2990 (1994)	
	C14	MALABARBA et al., "Structural Modifications of the Active Site in Teicoplanin and Related Glycopeptides. 1. Reductive Hydrolysis of the 1,2- and 2,3-Peptide Bonds", J. Org. Chem., Vol. 61, pp 2137-2150 (1996)	
	C15	MALABARBA et al., "Substitution of Amino Acids 1 and 3 in Teicoplanin Aglycon: Synthesis and Antibacterial Activity of Three First Non-natural Dalbaheptides", The Journal of Antibiotics, Vol. 50, pp 70-81 (1997)	
<i>DL</i>	C16	MALABARBA et al., "Synthesis and Biological Activity of Some Esters of the N-Acetylglucosaminyl Aglycone and of the Aglycone of Teicoplanin", The Journal of Antibiotics, Vol. XL, No. 11, pp 1572-1587 (1987)	
<i>DL</i>	C17	MALABARBA et al., "Synthesis and Biological Properties of N ⁸³ -Carboxamides of Teicoplanin Antibiotics. Structure-Activity Relationships", J. Med. Chem., Vol. 32, pp 2450-2460 (1989)	
	C18	NAGARAJAN, "Structure-Activity Relationships of Vancomycin-Type Glycopeptide Antibiotics", The Journal of Antibiotics, Vol. 46, No. 8, pp 1181-1195 (1993)	
	C19	NAGARAJAN et al., "Synthesis and Antibacterial Activity of N-Acyl Vancomycins", The Journal of Antibiotics, Vol. XLI, No. 10, pp 1430-1438 (1988)	
	C20	NAGARAJAN et al., "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins", The Journal of Antibiotics, Vol. XLII, No. 1, pp 63-72 (1989)	
	C21	NICOLAOU et al., "Chemistry, Biology, and Medicine of the Glycopeptides Antibiotics", Angew. Chem. Int. Ed., Vol. 38, pp 2096-2152 (1999)	
	C22	OLSFYEEVA et al., "Chemical Modification of Antibiotic Eremomycin at the Asparagine Side Chain", The Journal of Antibiotics, Vol. 52, No. 3, pp 319-324 (1999)	
	C23	PAVLOV et al., "A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity", The Journal of Antibiotics, Vol. 50, No. 6, pp 509-513 (1997)	
<i>DL</i>	C24	PAVLOV et al., "Chemical Modification of Glycopeptide Antibiotics [VC1], Russian Journal of Bioorganic Chemistry, Vol. 24, No. 9, pp 570-587 (1998)	
<i>DL</i>	C25	PAVLOV et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship", The Journal of Antibiotics, Vol. 51, No. 1, pp 73-78 (1997)	


Examiner Signature

David Lukton

Date Considered

10-18-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/092,088
Filing Date	March 6, 2002
First Named Inventor	J. Kevin JUDICE
Art Unit	1653
Examiner Name	David LUKTON

Attorney Docket Number

P-022-RC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JK</i>	C26	RODRIGUEZ et al., "Novel Glycopeptide Antibiotics: N-Alkylated Derivatives Active Against Vancomycin-Resistant Enterococci", Vol. 51, No. 6, pp 560-569 (1998)	
<i>JK</i>	C27	SHARMAN et al., "The Roles of Dimerization and Membrane Anchoring in Activity of Glycopeptide Antibiotics against Vancomycin-Resistant Bacteria", J. Am. Chem. Soc., Vol. 119, pp 12041-12047 (1997)	
<i>JK</i>	C28	SNYDER et al., "Enzymatic Deacylation of Teicoplanin Followed by Reductive Alkylation: Synthesis and Antibacterial Activity of New Glycopeptides", The Journal of Antibiotics, Vol. 51, No. 10, pp 945-951 (1998)	
<i>JK</i>	C29	STAROSKE et al., "Synthesis of Covalent Head-to-Tail Dimers of Vancomycin", Tetrahedron Letters 39, pp 4917-4920 (1998)	
<i>JK</i>	C30	SUNDRAM et al., "Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci", J. Am. Chem. Soc., Vol. 118, pp 13107-13108 (1996)	

Examiner Signature

David Lukton

Date Considered

10-18-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.